The Interleukin 2 Receptor in the Hypereosinophilic Syndrome

References

• Chusid M. J., Dale D. C., West B. C., Wolf S. M. The hypereosinophilic syndrome. Medicine 1975; 54: 1–26
   PubMed Web of Science ®Google Scholar
• Bush R. K., Geller M., Busse W. W., Faherty D. K., Dickie H. A. Response to corticosteroids in the hypereosinophilic syndrome: association with increased serum IgE levels. Arch. Intern. Med. 1978; 1388: 1244–6
   Google Scholar
• Spry C. J. F. The hypereosinophilic syndrome: Clinical features, laboratory findings and treatment. Allergy 1982; 37: 539–51
   PubMed Web of Science ®Google Scholar
• Tai P. C., Ackerman S. J., Spry C. J. F., Dunette S., Olsen E. G. J., Gleish G. J. Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophil endomyocardial diseases. Lancet 1987; 21: 643–7
   Google Scholar
• De Mello D. E., Uapis H., Jureidini S., Nomi S., Kephart G. M., Gleish G. J. Cardiac localization of eosinophil-granule major basic protein in acute necrotizing myocarditis. N. Eng. J. Med. 1990; 29: 1542–5
   Web of Science ®Google Scholar
• Noguchi H., Kephart G. M., Colby T. V., Gleish G. J. Tissue eosinophilia and eosinophil degranulation in syndromes associated with fibrosis. Am. J. Pathol. 1992; 140: 521–8
   PubMed Web of Science ®Google Scholar
• Flaum M. A., Schooley R. T., Fauci A. S., Gralnick H. R. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. I. Hematologic manifestations. Blood 1982; 58: 1012–20
   Web of Science ®Google Scholar
• Yoo T. J., Orman S. V., Patil S. R., Dorminey C., Needleman S., Rajtora D., Graves N., Ackerman L., Taylor W. W. Evolution to eosinophilic leukemia with a t(5:11) translocation in a patient with idiopathic hypereosinophilic syndrome. Cancer Genet. Cytogenet. 1984; 11: 389–94
   PubMed Web of Science ®Google Scholar
• Meeker T. C., Hardy D., William C., Hogan T., Abrams J. Activation of the interleukin-3 gene by chromosome translocation in acute lymphoblastic leukemia with eosinophil. Blood 1990; 76: 285–9
   PubMed Web of Science ®Google Scholar
• Grimaldi J. C., Meeker T. C. The t(5:14) chromosomal translocaticm in a case of acute lymphoblastic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. Blood 1989; 73: 2081–5
   PubMed Web of Science ®Google Scholar
• Sato A., Kobayashi K., Okabe H., Fukuda S. A case of the hypereosinophilic syndrome complicated by malignant lymphoma. J. Dermatol. 1983; 10: 75–80
   PubMedGoogle Scholar
• Greer J. P., York J. C., Cousar J. B., Mitchell R. T., Flexer J. M., Collins R. D., Stein R. S. Peripheral T-cell Lymphoma: A clinicopathologic study of 42 cases. J. Clin. Oncol. 1984; 2: 788–98
   PubMed Web of Science ®Google Scholar
• Merlio J. P., Demascarel A., Astiergin T., Michenet P., Beylot C., Beylot J. Eosinophilia associated with a composite lymphoma. Histopathology 1991; 18: 363–5
   PubMed Web of Science ®Google Scholar
• Watanabe K., Shinbo T., Kojima M., Naito M., Tanahashi N., Nara M. B-cell lymphoma associated with eosinophilia. Cancer 1989; 64: 1682–5
   PubMed Web of Science ®Google Scholar
• Keidan A. J., Catovsky D., Tavares D. C. J., Spry C. J. Hypereosinophilic syndrome preceding T cell lymphoblastic lymphoma. Clin. Lab. Haematol. 1985; 7: 83–8
   PubMedGoogle Scholar
• Kim C. I., Park S. H., Chi J. G. Idiopathic hypereosinophilic syndrome terminating as disseminated T-cell lymphoma. Cancer 1991; 67: 1064–9
   PubMed Web of Science ®Google Scholar
• Prin L., Lefebvre P., Gruart V., Capron M., Storme L., Formstecher P., Loiseau S., Capron A. Heterogeneity of human eosinophil glucocorticoid receptor expression in hypereosinophilic patients—Absence of detectable receptor correlates with resistance to corticotherapy. Clin. Exp. Immunol. 1989; 78: 383–9
   PubMed Web of Science ®Google Scholar
• Schooley R. T., Flaum M. A., Gralnick H. R., Fauci A. S. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations. Blood 1981; 58: 1021–8
   PubMed Web of Science ®Google Scholar
• Prin L., Capron M., Tonnel A. B., Bletry O., Capron A. Heterogeneity of human peripheral blood eosi-nophils: Variability in cell density and cytotoxic ability in relation to the level and the origin of hypereosinophilia. Int. Arch. Allergy., Appl. Immunol. 1983; 72: 336–46
   PubMedGoogle Scholar
• Caulfield J. P., Hein A., Rothenberg M. E., Owen W. F., Soberman R. J., Stevens R. L., Austen K. F. A morphometric study of normodense and hypodense human eosinophils that are derived in vivo and in vitro. Am. J. Pathol. 1990; 137: 27–41
   PubMed Web of Science ®Google Scholar
• Prin L., Charon J., Capron M., Cosset P., Taelman H., Tonnel A. B., Capron A. Heterogeneity of human eosinophils. II. Variability of respiratory burst activity related to cell density. Clin. Exp. Immunol. 1984; 57: 735–42
   PubMed Web of Science ®Google Scholar
• Gruart V., Balloul J. M., Prin L., Tomassini M., Loiseau S., Capron A., Capron M. Variations in protein expression related to human eosinophil heterogeneity. J. Immunol. 1989; 142: 4416–21
   PubMed Web of Science ®Google Scholar
• Basten A., Beeson P. B. Mechanism of eosinophilia. II. Role of the lymphocyte. J. Exp. Med. 1970; 131: 1288–305
   PubMed Web of Science ®Google Scholar
• Sonoda Y., Arai N., Ogawa M. Humoral regulation of eosinophilopoiesis in vitro: analysis of targets of interleukin-3, granulocyte/macrophage colony-stimulating factor (GM-CSF), and interleukin-5. Leukemia 1989; 3: 14–8
   PubMed Web of Science ®Google Scholar
• Clutterbuck E. J., Hirst E. M., Sanderson C. J. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-I, IL-3, IL-6, and GM-CSF. Blood 1989; 73: 1504–12
   PubMed Web of Science ®Google Scholar
• Saito H., Hatake K., Dvorak A. M., Leiferman K. M., Donnenberg A. D., Arai N., Ishizaka K., Ishizaka T. Selective differentiation and proliferation of hemato-poietic cells induced by recombinant human interleukins. Proc. Natl Acad. Sci. USA 1989; 85: 2288–92
   Web of Science ®Google Scholar
• Rothenberg M. E., Owen W. F. J., Silberstein D. S., Woods J., Soberman R. J., Austen K. F., Stevens R. L. Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin-3. J. Clin. Invest. 1988; 81: 1986–92
   PubMed Web of Science ®Google Scholar
• Owen W. F. J., Rothenberg M. E., Silberstein D. S., Gasson J. C., Stevens R. L., Austen K. F., Soberman R. J. Regulation of human eosinophil viability, density, and function by granulocyte-macrophage colony-stimulating factor in the presence of 3T3 fibroblasts. J. Exp. Med 1987; 166: 129–41
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y., Hayashi Y., Sugama Y., Miura Y., Kasahara T., Kitamura S., Torisu M., Mita S., Tominaga A., Takatsu K., Suda T. Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. J. Exp. Med 1988; 167: 1737–42
   PubMed Web of Science ®Google Scholar
• Lopez A. F., Sanderson C. J., Gamble J. R., Campbell H. D., Young I. G., Vadas M. A. Recombinant human interleukin 5 is a selective activator of human eosinophil function. J. Exp. Med. 1988; 00: 219–24
   Web of Science ®Google Scholar
• Sher A., Coffman R. L., Hieny S., Scott P., Cheever A. W. Interleukin-5 is required for the blood and tissue eosinophilia but not granuloma formation induced by infection with. Schistosoma mansoni. Proc. Natl. Acad. Sci. USA. 1990; 87: 61–5
   PubMed Web of Science ®Google Scholar
• Limaye A. P., Abrams J. S., Silver J. E., Ottesen E. A., Nutman T. B. Regulation of parasite-induced eosinophilia—Selectively increased interleukin-5 production in helminth-infected patients. J. Exp. Med. 1990; 172: 399–402
   PubMed Web of Science ®Google Scholar
• Hamid Q., Azzawi M., Ying S., Moqbel R., Wardlaw A. J., Corrigan C. J., Bradley B., Durham S., Collins J. V., Jeffery P. K., Quint D. J., Kay A. B. Interleukin-5 messenger RNA in mucosal bronchial biopsies from asthmatic subjects. Int. Arch. Allergy Appl. Immunol. 1991; 94: 169–70
   PubMedGoogle Scholar
• McDonald D., Gordon A. A., Kajitani H., Enokihara H., Barrett A. J. Interleukin-2 treatment-associated eosinophilia is mediated by interleukin-5 production. Br. J. Haematol. 1990; 76: 168–73
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y., Suda T., Shiozaki H., Miura Y., Hitoshi Y., Tominaga A., Takatsu K., Kasahara T. Role of IL-5 in IL-2-induced eosinophilia—In vivo and in vitro expression of IL-5 messenger RNA by IL-2. J. Immunol. 1990; 145: 873, 7.
   PubMed Web of Science ®Google Scholar
• Owen W. F., Rothenberg M. E., Petersen J., Weller P. F., Silberstein D., Sheffer A. L., Stevens R. L., Soberman R. J., Austen K. F. Interleukin 5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome. J. Exp. Med. 1989; 170: 343–8
   PubMed Web of Science ®Google Scholar
• Enokihara H., Kajitani H., Nagashima S., Tsunogake S., Takano N., Saito K., Furusawa S., Shishido H., Hitoshi Y., Takatsu K. Interleukin-5 activity in sera from patients with eosinophilia. Br. J. Haematol. 1990; 75: 458–62
   PubMed Web of Science ®Google Scholar
• Enokihara H., Furusawa S., Nakakubo N., Kajitani H., Nagashima S., Saito K., Shishido H., Hitoshi Y., Takatsu K., Noma T., Shimizu A., Honjo T. T cells from eosinophilic patients produce interleukin-5 with interleukin-2 stimulation. Blood 1989; 73: 1809–13
   PubMed Web of Science ®Google Scholar
• Morgan D. A., Ruscetti F. W., Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976; 193: 1007–8
   PubMed Web of Science ®Google Scholar
• Robb R. J., Munck A., Smith K. A. T-cell growth factor receptors: quantitation. specificity and biological relevance. J. Exp Med. 1981; 154: 1455–74
   PubMed Web of Science ®Google Scholar
• Leonard W. J., Krönke M., Peffer N. J., Depper J. M., Greene W. C. Interleukin-2 receptor gene expression in normal human T lymphocytes. Proc. Natl. Acad, Sci. USA 1985; 82: 6281–5
   PubMed Web of Science ®Google Scholar
• Leonard W. J., Depper J. M., Grabtree G. R., Rudikoff S., Puinphrey J., Robb R. J., Krönke M., Svetlik P. B., Peffer N. J., Waldmann T. A., Greene W. C. Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. Nature 1984; 311: 626–31
   PubMed Web of Science ®Google Scholar
• Nikaido T., Shimizu A., Ishida N., Sabe H., Teshigawara K., Maeda M., Uchiyama T., Yodoi J., Honjo T. Molecular cloning of cDNA encoding human interleukin-2 receptor. Nature 1984; 311: 631–5
   PubMed Web of Science ®Google Scholar
• Cosman D., Cerretti D. P., Larsen A., Park L., March L., Dower S., Gillis S., Urdal D. Cloning, sequencing and expression of human interleukin-2 receptor. Nature 1984; 312: 768–71
   PubMed Web of Science ®Google Scholar
• Leonard W. J., Depper J. M., Kanehisa M., Krönke M., Peffer N. J., Svetlik P. B., Sullivan M., Greene W. C. Structure of the human interleukin-2 receptor gene. Science 1985; 230: 633–9
   PubMed Web of Science ®Google Scholar
• Sharon M., Klausner R. D., Cullen B. R., Chizzonite R., Leonard W. J. Novel interleukin-2 receptor subunit detected by cross-linking under high affinity conditions. Science 1986; 234: 859–63
   PubMed Web of Science ®Google Scholar
• Tsudo M., Kozak R. W., Coldman C. K., Waldmann T. A. Demonstration of a non-Tac peptide that binds interleukin-2: a potential participant in a multichain interleukin-2 receptor complex. Proc. Natl. Acad. Sci. USA 1986; 83: 9694–8
   PubMed Web of Science ®Google Scholar
• Teshigawara K., Wang H. M., Kato K., Smith K. A. Interleukin-2 high-affinity receptor expression requires two distinct binding proteins. J. Exp. Med. 1987; 165: 223–38
   PubMed Web of Science ®Google Scholar
• Robb R. J., Rusk C. M., Yodoi J., Greene W. C. Interleukin-2 binding molecule distinct from the Tac protein: analysis of its role in formation of high-affinity receptors. Proc. Natl. Acad. Sci. USA 1987; 84: 2002–6
   PubMed Web of Science ®Google Scholar
• Hatakeyama M., Tsudo M., Minamoto S., Kono T., Doi T., Miyata T., Miyasaka M., Taniguchi T. Interleukin-2 receptor beta-chain gene: Generation of three receptor forms by cloned human alpha and beta chain cDNA's. Science 1989; 244: 551–6
   PubMed Web of Science ®Google Scholar
• Shibuya H., Yoneyama M., Nakamura Y., Harada H., Hatakeyama M., Minarnoto S., Kono T., Doi T., White R., Taniguchi T. The human interleukin-2 receptor beta-chain gene—Genomic organization, promoter analysis and chromosomal assignment. Nucleic. Acids. Res. 1990; 18: 3697–703
   PubMed Web of Science ®Google Scholar
• Gnarra J. R., Otani H., Wang M. G., McBride O. W., Sharon M., Leonard W. J. Human interleukin-2 receptor beta-chain gene—Chromosomal localization and identification of 5′ regulatory sequences. Proc. Natl. Acad. Sci. USA 1990; 87: 3440–4
   PubMed Web of Science ®Google Scholar
• Tsudo M., Karasuyama H., Kitamura F., Nagasaka Y., Tanaka T., Miyasaka M. Reconstitution of a functional IL-2 receptor by the beta-chain cDNA—A newly acquired receptor transduces negative signal. J. Immunol. 1989; 143: 4039–43
   PubMed Web of Science ®Google Scholar
• D'Andrea A. D., Fasman C. D., Lodish H. F. Erythropoietin receptor and interleukin-2 receptor beta-chain: A new receptor family. Cell 1989; 58: 1023–4
   PubMed Web of Science ®Google Scholar
• Bazan J. F. A novel family of growth factor receptors: A common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain. Biochern. Biophys. Res. Commun. 1989; 164: 788–93
   PubMed Web of Science ®Google Scholar
• Cosman D., Lyman S. D., Ldzerda R. L., Beckmann M. P., Park I. S., Goodwin R. G., March C. J. A new cytokine receptor superfanlily. Trends. Biochem. Sci. 1990; 15: 265–70
   PubMed Web of Science ®Google Scholar
• Audrain M., Boefiard K., Soulillou J. P., Jacques Y. Synergistic action of monoclonal antibodies directed at p55 and p75 chains of the human IL.-2-receptor. J. Immunol. 1991; 146: 884–92
   PubMed Web of Science ®Google Scholar
• Kaye J., Gillis S., Mizel S. B., Shevach F. M., Malex T. R., Dinarello C. A., Lachman L. B., Janeway C. A. J. Growth of a cloned helper T cell line induced by a monoclonal antibody specific for the antigen receptor: interleukin-I is required for the expression of receptors for interleukin-2. J. Immunol. 1984; 133: 1339–45
   PubMed Web of Science ®Google Scholar
• Shirakawa R., Tanaka Y., Eto S., Suzuki H., Yodoi J., Yamashlta U. Effect of interleukin 1 on the expression of interleukin 2 receptor (Tac antigen) on human natural killer cells and natural killer-like cell line (YT cells). J. Immunol. 1986; 137: 551–6
   PubMed Web of Science ®Google Scholar
• Plaetinck G., Combe M. C., Corthesy P., Sperisen P., Kanamori H., Honjo T., Nabholz M. Control of IL-2 receptor-alpha expression by IL-I, Tumor Necrosis Factor, and IL-2 Complex regulation via elements in the 5′ flanking region. J. Immunol. 1990; 145: 3340–7
   PubMed Web of Science ®Google Scholar
• Lee J. C., Truneh A., Smith M. F., Tsang K. Y. Induction of interleukin 2 receptor (Tac) by tumor necrosis factor in YT cells. J. Immunol. 1987; 139: 1935–8
   PubMed Web of Science ®Google Scholar
• Lowenthal J. W., Ballard D. W., Bogerd H., Böhnlein E., Greene W. C. Tumor necrosis factor-alpha activation of the IL-2 receptor-alpha gene involves the induction of kB-specific DNA binding proteins. J. Immunol. 1989; 142: 3121–8
   PubMed Web of Science ®Google Scholar
• Hara M., Kitani A., Harigai M., Hirose T., Suzuki K., Kawakami M., Ishizuka T., Kawaguchi Y., Hidaka T., Kawagoe M., Nakamura H. Interleukin-5 up-regulates high-affinity interleukin-2 receptor expression by human resting peripheral-T cells -A comparison with the effect of interleukin-4 on B-cells. Cytokine 1991; 3: 584–92
   PubMed Web of Science ®Google Scholar
• Smith K. A., Cantrell D. A. Interleukin-2 regulates its own receptors. Proc. Natl. Acad. Sci. USA 1985; 82: 864–8
   PubMed Web of Science ®Google Scholar
• Jankovic D. L., Gibert M., Baran D., Ohara J., Paul W. E., Theze J. Activation by IL-2, but not IL-4, up-regulate the expression of the p55 subunit of the IL-2 receptoron IL-2-and IL-4-dependen-t T cell lines. J. Imniunol. 1989; 142: 3313–20
   Google Scholar
• Martinez O. M., Gibbons R. S., Garovoy M. R., Aronson F. R. IL4 inhibits IL-2 receptor expression and IL-2-dependent proliferation of human T cells. J. Immunol. 1990; 144: 2211–5
   PubMed Web of Science ®Google Scholar
• Lindqvist C., Nihlmark E. L., Nordstrom T., Andersson L. C. Interleukin-4 down-regulates the p70-chain of the IL-2 receptor on peripheral blood mononuclear cells. Cell. Immunol. 1991; 136: 62–8
   PubMed Web of Science ®Google Scholar
• Onishi R., Ishikawa T., Kodaka T., Okuma M., Uchiyama 'T. Interleukin-3-induced down-regulation of the expression of interleukin-2 receptor-beta chain in human T-cells. Blood 1991; 78: 2908–17
   PubMed Web of Science ®Google Scholar
• Krönke M., Leonard W. J., Depper J., Greene W. C. Deregulation of interleukin-2 receptor gene expression in HTLV-I-induced adult T-cell leukemia. Science 1985; 228: 1215–7
   PubMed Web of Science ®Google Scholar
• Tagaya Y., Maeda Y., Mitsui A., Kondo N., Matsui H., Hamuro J., Brown N., Arai K.-I., Yokota T., Wagasugi H., Yodoi J. ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin; possible involvement of dithiol-reduction in the II-2 receptor induction. Embo. J. 1989; 8: 757–64
   PubMed Web of Science ®Google Scholar
• Rubin L. A., Kurman C. C., Fritz M. E., Biddison W. E., Boutin B., Yarchoan R., Nelson D. L. Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J. Immunol. 1985; 135: 3172–7
   PubMed Web of Science ®Google Scholar
• Josimovic-Alasevic O., Herrman T., Diamantstein T. Demonstration of two distinct forms of released low-affinity type interleukin-2 receptors. Eur J. Immunol. 1988; 11: 1855–7
   Web of Science ®Google Scholar
• Tsudo M., Karasuyama H., Kitamura F., Tanaka T., Kubo S., Yamamura Y., Tamatani T., Hatakeyama M., Taniguchi T., Miyasaka M. The IL-2 receptor beta-chain (P70)-Ligand binding ability of the cDNA-encoding membrane and secreted forms. J. Immunol. 1990; 145: 599–606
   PubMed Web of Science ®Google Scholar
• Honda M., Kitamura K., Takeshita T., Sugamura K., Tokunaga T. Identification of a soluble IL-2 receptor beta-chain from human lymphoid cell line cells. J. Immunol. 1990; 145: 4131–5
   PubMed Web of Science ®Google Scholar
• Dummer R., Posseckert G., Nestle F., Witzgall R., Burger M., Becker J. C., Schafer E., Wiede J., Sebald W., Burg G. Soluble interleukin-2 receptors inhibit interleukin 2-dependent proliferation and cytotoxicity—Explanation for diminished Natural Killer cell activity in Cutaneous T-cell Lymphomas in vivo. J. Invest. Dermatol. 1992; 98: 50–4
   PubMed Web of Science ®Google Scholar
• Mosley B., Beckmaiin M. P., March C. J., Idzerda R. L., Gimpel S. D., Vander Bos T., Friend D., Alpert A., Anderson D., Jackson J., Wignall J. M., Smith C., Gallis B., Sims J. E., Urdal D., Widmer M. B., Cosman D., Park L. S. The murine interleukin-4 receptor: Molecular cloning and characterization of secreted and membrane bound forms. Cell 1989; 59: 335–48
   PubMed Web of Science ®Google Scholar
• Galizzi J. P., Zuber C. E., Harada N., Gorman D. M., Djossou O., Kastelein R., Banchereau J., Howard M., Miyajima A. Molecular cloning of a cDNA encoding the human interleukin-4 receptor. Int. Immunol. 1990; 2: 669–75
   PubMed Web of Science ®Google Scholar
• Goodwin R. G., Friend D., Zielger S., Jerzy R., Falk B. A., Gimpel S., Cosman D., Dower S. K., March C. J., Namen A. E., Park L. S. Cloning of the human and murine interleukin-7 receptor: Demonstration of a soluble form and homology to a new receptor super family. Cell 1990; 60: 941–51
   PubMed Web of Science ®Google Scholar
• Tawnier J., Devos R., Cornelis S., Tuypens T., Vanderhey-Den J., Fiers W., Plaetinck G. A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific alpha-chain and a beta-chain shared with the receptor for GM-CSF. Cell 1991; 66: 1175–84
   PubMed Web of Science ®Google Scholar
• Chilosi M., Semenzato G., Vinante F., Menestrina F., Piazzola E., Focchiatti V., Sabbioni R., Zanotti R., Pizzolo G. Increased levels of soluble interleukin-2 receptor in Non-Hodgkin's lymphomas. Am. J. Clin. Pathol. 1989; 1989: 186–91
   Google Scholar
• Yasuda N., Lai P. K., Ip S. H., Kung P. C., Hinuma Y., Matsuoka M., Hattori T., Takatsuki K., Purtilo D. T. Soluble IL-2 receptors in sera of Japanese patients with adult T cell leukemia mark activity of disease. Blood 1988; 71: 1021–6
   PubMed Web of Science ®Google Scholar
• Richards J. M., Mick R., Latta J. M., Daly K., Ratain M. J., Vardiman J. W., Golomb H. M. Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia. Blood 1990; 76: 1941–5
   PubMed Web of Science ®Google Scholar
• Motoi T., Uchiyama T., Hori T., Itoh K., Uchino H., Ueda R. Elevated serum-soluble interleukin-2 receptor (Tac antigen) levels in Chronic Myelogenous Leukemia patients with blastic crisis. Blood 1989; 74: 1052–7
   PubMed Web of Science ®Google Scholar
• Rubin L. A., Nelson D. L. The soluble interleukin-2 receptor—Biology, function, and clinical application. Ann. Intern. Med. 1990; 113: 619–27
   PubMed Web of Science ®Google Scholar
• Prin L., Plumas J., Gruart V., Loiseau S., Aldebert D., Ameisen J. C., Vermersch A., Fenaux P., Bletry O., Capron M. Elevated serum levels of soluble interleukin-2 receptor: a marker of disease activity in the hypereosinophilic syndrome. Blood 1991; 78: 2626–32
   PubMed Web of Science ®Google Scholar
• Parillo F., Fauci A. S., Wolff S. M. Therapy of the hypereosinophilic syndrome. Ann. Inter. Med. 1978; 89: 167–78
   PubMed Web of Science ®Google Scholar
• Murphy P. T., Fennelly D. F., Sturart M., O'Donnell J. R. Alpha interferon in a case of hypereosinophilic syndrome. Br. J. Haematol. 1990; 75: 619–20
   PubMed Web of Science ®Google Scholar
• Zielinski R. M., Lawrence W. D. Interferon alpha for the hypereosinophilic syndrome. Ann. Intern. Med. 1990; 113: 716–8
   PubMed Web of Science ®Google Scholar
• Broxmeyer H. E., Lu L., Platzer E., Feit C., Juliano L., Berish R. Y. Comparative analysis of the influences of human gamma, alpha, and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granu-locyte-macrophage (CFU-GM) progenitor cells. J. Immunol. 1983; 131: 1300–5
   PubMed Web of Science ®Google Scholar
• Yoshida M., Mioshi I., Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its application in the disease. Proc. Natl. Acad. Sci. USA 1982; 79: 2031–5
   PubMed Web of Science ®Google Scholar
• Shimoyama M., Minato K., Tobinai K., Nagai M., Setoya T., Takenaka T., Ishihara K., Watanabe S., Hoshino H., Miwa M., Kinoshita M., Okabe S., Fukushima N., Inada S. Atypical adult T-cell leukemia/lymphoma. Diverse clinical manifestations T-cell leukemia/lymphoma. Jpn. J. Clin. Oncol 1983; 13: 165–8, suppl. 2
   PubMed Web of Science ®Google Scholar
• Vukelja S. J., Weiss R. B., Perry D. J., Longo D. L. Eosinophilia associated with Adult T-cell Leukemia/ lymphoma. Cancer 1988; 62: 1527–30
   PubMed Web of Science ®Google Scholar
• Prin L., Leguern M., Ameisen J. C., Saragosti S., Bletry O., Fenaux P., Levy J. P., Capron A. HTLV-I and malignant hypereosinophilic syndrome. Lancet 1988; 2: 569
   PubMed Web of Science ®Google Scholar
• Cross S. L., Feinberg M. B., Wolf J. B., Holbrook N. J., Wong-Staal F., Leonard W. J. Regulation of the human interleukin-2 receptor alpha chain promoter: activation of the nonfunctional promoter by the transactivator gene of HTLV-I. Cell 1987; 49: 47–56
   PubMed Web of Science ®Google Scholar
• Nimer S. D., Gasson J. C., Hu K., Smalberg I., Williams J. L., Chen I. S. Y., Rosenblatt J. D. Activation of the GM-CSF promoter by HTLV-I and -II tax proteins. Oncogene 1989; 4: 671–6
   PubMed Web of Science ®Google Scholar
• Noma T., Nakukubo H., Sugita M., Kumagai S., Maeda M., Shimizu A., Honjo T. Expression of different combinations of interleukins by human T-cell leukemic cell lines that are clonally related. J. Exp. Med. 1989; 169: 1853–8
   PubMed Web of Science ®Google Scholar
• Oka T., Ohtsuki Y., Sonobe H., Furihata M., Miyoshi I. Suppressive effects of interferons on the production and release of human T-lymphotropic virus type-I (HTLV-I). Arch. Virol. 1990; 115: 63–73
   PubMed Web of Science ®Google Scholar
• Sayar D., Ketzinel M., Gerez L., Silberberg C., Reshef A., Kaempfer R. Expression of the human IL-2 receptor on lymphocytes involves rapid turnover of its p55 α-subunit (Tac). J. Immunol. 1990; 145: 2946–9
   PubMed Web of Science ®Google Scholar
• Loughnan M. S., Sanderson C. J., Nossal G. J. V. Soluble interleukin 2 receptors are released from the cell surface of normal B lymphocytes stimulated with interleukin 5. Proc. Natl. Acad. Sci. USA 1988; 85: 3115–9
   PubMed Web of Science ®Google Scholar
• Lotze M. T., Matory Y. T., Rayner A. A., Ettinghausen S. E., Vetto J. T., Seipp C. A., Rosenberg C. A. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 1986; 58: 2764–72
   PubMed Web of Science ®Google Scholar
• McDonald D., Jiang Y. Z., Gordon A. A., Mahendra P., Oskam R., Palmer P. A., Franks C. R., Barrett A. J. Recombinant interleukin-2 for acute myeloid leukaemia in first complete remission—A pilot study. Leuk. Res 1990; 14: 967–73
   PubMed Web of Science ®Google Scholar
• Foa R., Meloni G., Tosti S., Novarino A., Fenu S., Gavosto F., Mandelli F. Treatment of acute myeloid leukaemia patients with recombinant interleukin-2-A pilot study. Br. J. Haematol. 1991; 77: 491–6
   PubMed Web of Science ®Google Scholar
• Plumas J., Gruart V., Aldebert D., Truong M. J., Capron M., Capron A., Prin L. Human eosinophils from hypereosinophilic patients spontaneously express the p55 but not the p75 IL-2 receptor subunit. Eur. J. Immunol. 1991; 21: 1265–70
   PubMed Web of Science ®Google Scholar
• Riedel D., Lindemann A., Brach M., Mertelsmann R., Herrmann F. Granulocyte-macrophage colony-stimulating factor and interleukin-3 induce surface expression of interleukin-2 receptor p55-chain and CD4 by human eosinophils. Immunology 1990; 70: 258–61
   PubMed Web of Science ®Google Scholar
• Rand T. H., Silberstein D. S., Kornfeld H., Weller P. F. Human eosinophils express functional interleukin-2 receptors. J. Clin. Invest. 1991; 88: 825–32
   PubMed Web of Science ®Google Scholar
• Chihara J., Gruart V., Plumas J., Tavernier J., Kusnierz J. P., Prin L., Capron A., Capron M. Induction of CD23, CD25 and CD4 expression on an eosinophilic cell line (EoL-3) by interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-5 (IL-5). Eur. Cyiokine Netw. 1992; 3: 53–61
   PubMedGoogle Scholar
• Kita H., Ohnishi T., Okubo Y., Weiler D., Abrams J. S., Gleich G. J. Granulocyte/macrophage colony-stimulating factor and interleukin-3 release from human peripheral blood eosinophils and neutrophils. J. Exp. Med. 1991; 174: 745–8
   PubMed Web of Science ®Google Scholar
• Moqbel R., Hamid Q., Ying S., Barkans J., Hartnell A., Tsicopoulos A., Wardlaw A. J., Kay A. B. Expression of messenger RNA and immunoreactivity for the Granulocyte/macrophage colony-stimulating factor in activated human eosinophils. J. Exp. Med. 1991; 174: 749–52
   PubMed Web of Science ®Google Scholar
• Desreumaux P., Janin A., Colombel J. F., Prin L., Plumas J., Emilie D., Torpier G., Capron A., Capron M. Interleukin 5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with Coeliac disease. J. Exp. Med. 1991; 175: 293–6
   Web of Science ®Google Scholar
• Sedgwick J. B., Frick W. E., Sondel P. M., Hank J. A., Borden E., Busse W. W. The appearance of hypodense eosinophils during interleukin-2 treatment. J. Allergy. Clin. Immunol. 1990; 85: 557–66
   PubMed Web of Science ®Google Scholar
• Silberstein D. S., Schoof D. D., Rodrick M. L., Tai P.-C., Spry C. J.F., David J. R., Eberlein T. J. Activation of eosinophils in cancer patients treated with IL-2 and IL-2-generated lymphokine-activated killer cells. J. Immunol. 1989; 142: 2162–7
   PubMed Web of Science ®Google Scholar